Safe Antidepressants During Pregnancy: A Clinical Guide

Could the medication you’re worried about also be part of protecting your health? Asking whether antidepressants are safe during pregnancy is completely understandable, but there isn’t one answer for everyone. The choice depends on your symptoms, treatment history, and the possible risks and benefits of each option.

You may be weighing concerns about your baby against the fear that depression could return if you stop or switch medication. Both deserve careful attention. Antidepressants can be an important part of treatment when clinically appropriate, and stopping suddenly can increase the risk of relapse. You don’t have to navigate that tension alone.

This guide explains what is known about medication risks during pregnancy and breastfeeding, why a medicine that works for one person may not suit another, and what to consider before continuing, changing, or tapering treatment. We’ll also cover newborn adjustment after exposure and research on children’s longer-term outcomes, helping you prepare for a clearer conversation about your care.

What are the risks and benefits of taking antidepressants while pregnant or breastfeeding?

Antidepressant decisions during pregnancy involve weighing potential medication effects against the effects of untreated or undertreated depression. The right balance depends on the specific treatment and your mental health needs.

Treatment Benefits and Medication Risks

Antidepressants can be an important part of care for pregnant women diagnosed with depression or anxiety when clinically indicated. The American College of Obstetricians and Gynecologists discusses medication treatment in its guidance on mental health conditions during pregnancy and postpartum.

Treatment can help manage symptoms that affect your wellbeing. Medication exposure also deserves consideration, since possible effects vary by medicine and timing. A useful discussion addresses these factors separately rather than treating all medication as one risk category. Breastfeeding can add another consideration: sertraline is generally considered a first-line antidepressant partly because little of it passes into breast milk.

Effects of Untreated Depression

Untreated depression can carry risks for the pregnant person and the pregnancy. It is associated with preterm birth and low birth weight, and risks can include preeclampsia and suicide. These associations do not predict the outcome of an individual pregnancy, but they make untreated symptoms part of the same risk-benefit discussion as medication exposure.

Depression can continue into the postpartum period. Depression during pregnancy may be one risk factor for postpartum depression, though it is not the only one. This makes symptom management relevant beyond delivery, especially when considering how treatment needs may change after birth. Anxiety also deserves attention when it is part of your diagnosis or symptoms.

Pregnancy and Birth Outcomes

Do antidepressants increase the risk of birth defects, miscarriage, or preterm birth? Some studies link paroxetine exposure during the first trimester to a small but significant risk of cardiovascular defects in babies. Untreated or undertreated depression is associated with preterm birth and low birth weight.

These findings involve different exposures and outcomes. They do not show that all antidepressants carry the same risks or that medication alone explains a pregnancy outcome. The specific drug, timing, and effects of depression all matter. A careful discussion keeps these factors distinct rather than reducing the decision to a simple yes-or-no answer about medication.

Newborn Adaptation and Pulmonary Hypertension

Newborn adaptation symptoms can appear in the first few days after birth following SSRI exposure. About one-third of newborns exposed to antidepressants during the second half of pregnancy may show symptoms, which usually resolve within two weeks. This information can help families understand what newborn observation may involve.

Persistent pulmonary hypertension of the newborn is another reported concern associated with SSRIs. The relative increase is about 1.5 times the average, while the estimated absolute risk is less than 1-2 per 1,000 pregnancies. An SSRI or SNRI taken in the month before giving birth is also associated with a small increase in heavy bleeding during the first 24 hours after birth. These are specific risks to weigh, not a reason to stop treatment abruptly.

Essential Reads: What is the Best Antidepressant to Use During Pregnancy?

There isn’t one antidepressant that is best for every pregnancy. The choice depends on the specific medicine, your symptoms, treatment history, and preferences.

Safety Evidence Across Antidepressant Classes

Research on reproductive safety examines different medicines and outcomes, so findings about one antidepressant may not answer questions about another. Selective serotonin reuptake inhibitors (SSRIs) are a widely used class; about 8% of pregnant women receive treatment with SSRIs. That figure describes use, not a safety ranking or a recommendation for every patient.

Serotonin-norepinephrine reuptake inhibitors (SNRIs) are a separate medication class. Comparing an SSRI with an SNRI means considering the specific medicines and available evidence, not relying on the class names alone. This distinction helps prevent a broad research finding from being treated as a prediction about one person’s pregnancy.

Safety of Specific Antidepressants

Sertraline, fluoxetine, escitalopram, and citalopram are SSRIs; venlafaxine and desvenlafaxine are SNRIs. Medicines in the same class are not interchangeable. Consider the evidence and your past response for the specific medicine being discussed, rather than assuming findings for one drug apply to all six.

Sertraline illustrates why dose and response also matter. Its typical starting dose is 50 mg, while many individuals may need 150 mg to 200 mg to manage symptoms effectively. These dosing details are not pregnancy-specific instructions; Mayo Clinic’s sertraline dosage information describes dosing as a treatment matter, not a reason to adjust medication on your own.

Trimester and Dose Considerations

Pregnancy stage and dose describe different aspects of medication exposure. Stage helps establish when exposure occurs, while dose describes how much medicine is taken. Neither detail alone determines whether a medicine is suitable. The specific antidepressant and its role in managing symptoms also matter.

How do risks differ by trimester and dose? Some concerns relate to particular exposure periods, and dose is considered alongside the medicine and treatment response. Another person’s dose does not establish the right dose for you. Avoid changing a prescribed amount based only on general figures or information about another pregnancy.

Medical Guideline Recommendations

Guidance from the American College of Obstetricians and Gynecologists recognizes antidepressants as an important part of care when clinically indicated. Its guideline on mental health conditions during pregnancy and postpartum addresses treatment during these stages.

This guidance does not mean every pregnant person should take the same medication. Your clinical history and preferences help shape the choice. Discuss which treatments you have used, how they affected your symptoms, and what matters most to you. Those details make the conversation more specific than choosing a medicine from a general “safest” list.

Continuing treatment versus switching medications

Deciding whether to continue or change an antidepressant means comparing two treatment paths, not choosing between risk and no risk. Your current response, past treatment experience, and reasons for considering a change help frame the decision.

When continuing treatment may make sense

A medication that has kept your symptoms manageable is useful information when planning for pregnancy. Consider how consistently it has worked, whether symptoms returned during past changes, and what side effects you experience. These details help clarify the value of maintaining a stable treatment approach.

That doesn’t mean continuing is automatically the right choice. The specific medicine and your health history still matter. The American College of Obstetricians and Gynecologists’ guidance on mental health treatment during pregnancy addresses care decisions in this setting. Use your own treatment history to make the discussion specific.

When switching is considered

A switch may be discussed if symptoms remain difficult to manage, side effects interfere with daily life, or a medication-specific concern changes the balance. Before considering a new medicine, clarify what the proposed change is meant to address. Is the goal better symptom control, fewer side effects, or a different exposure profile?

Then compare the likely benefit of the change with the possibility of losing symptom control during the transition. A previous good response to another medicine may be relevant, but it doesn’t guarantee the same response now. The decision should account for why your current treatment is being reconsidered and which outcomes matter most to you.

Why stopping suddenly can backfire

Stopping an SSRI abruptly during pregnancy or postpartum is associated with an increased risk of depression relapse, especially for people with severe depression. Sudden discontinuation can also cause symptoms such as nausea, insomnia, or flu-like feelings. ACOG guidance discusses the importance of weighing treatment decisions against the risk of illness returning.

These effects can complicate the picture: symptoms may reflect discontinuation, returning depression, or both. Note when changes begin and what you notice, then share that timeline with your care team. A clear sequence can help distinguish a medication transition effect from a return of the original condition.

Planning a medication change

If you want to stop or switch, discuss a gradual taper or transition plan with your provider rather than changing your dose on your own. The plan can account for your medication and treatment history, as well as how your symptoms will be monitored during the change.

Before the conversation, write down your medication and dose, what prompted the change, and any past difficulties during treatment adjustments. Ask which symptoms should prompt follow-up and when the plan will be reviewed. A shared plan gives you a clearer way to respond if your mental health shifts during pregnancy or postpartum.

Long-term outcomes in children exposed to antidepressants

Available findings offer some reassurance, but they don’t prove that every medication has identical effects. A large study reported in JAMA Internal Medicine found no increased risk of autism spectrum disorder, learning disabilities, or attention-deficit/hyperactivity disorder among children whose mothers took antidepressants during pregnancy.

What long-term studies can tell us

Studies of children’s development examine outcomes beyond pregnancy and birth, such as learning, behavior, and diagnoses. The JAMA Internal Medicine finding addresses three specific outcomes: autism spectrum disorder, learning disabilities, and attention-deficit/hyperactivity disorder. It does not mean researchers evaluated every possible aspect of children’s mental health or development.

That distinction matters when you read a study headline. A finding about those three outcomes can inform a discussion about them, but it cannot answer every question about a child’s future. Nor should it be treated as proof that antidepressant exposure has no possible effects. Research is most useful when the exact outcomes studied and the study’s limits are clear.

What paroxetine research adds

The Motherisk Program reported outcomes for over 3000 infants exposed to paroxetine. That provides a substantial group for examining outcomes after exposure to a specific antidepressant. Paroxetine is one medication, however, so results about it should not automatically be applied to sertraline, fluoxetine, or other antidepressants.

The previous section discussed concerns about first-trimester paroxetine exposure and cardiovascular defects. Birth outcomes and longer-term development are different questions. A study focused on infant outcomes can add information, but its findings should be understood in the context of the specific medicine and outcomes it examined.

Making sense of findings for your family

When you encounter a study, notice which medication it examined and which child outcomes it measured. For example, the JAMA Internal Medicine report addressed autism spectrum disorder, learning disabilities, and attention-deficit/hyperactivity disorder. The Motherisk Program reported on over 3000 infants exposed to paroxetine. These findings answer different questions, so they are not interchangeable.

It also helps to distinguish the effects being studied from the reason a parent needed treatment. Depression and anxiety can affect a parent’s mental health during pregnancy and after birth. A thoughtful decision considers medication evidence alongside the value of keeping symptoms managed, rather than focusing only on exposure.

For many parents, uncertainty about a child’s future development can feel especially heavy. Findings on autism spectrum disorder, learning disabilities, and attention-deficit/hyperactivity disorder are reassuring for those specific outcomes, while leaving room for continued research and individualized treatment decisions.

Choosing an antidepressant during pregnancy

The best choice depends on your clinical history and preferences, not pregnancy alone. Your symptoms, past response to medication, and plans for postpartum care all help shape the discussion.

Discuss your diagnosis, current symptoms, medication name and dose, past treatment response, and pregnancy or breastfeeding plans with your doctor. Ask how continuing, switching, or gradually tapering treatment could affect symptom control and relapse risk.

A practical starting point is the medicine you take now and how well it has worked. If sertraline has controlled your symptoms, that response is relevant alongside evidence about its reproductive safety. If a medication has not helped or causes difficult side effects, those details matter too. The goal is to compare realistic options, not choose a drug by name alone.

Your clinical history gives that comparison meaning. Tell your doctor which treatments you have tried, which helped, and whether symptoms returned after a previous change. For example, someone with a history of severe depression and relapse after stopping treatment may weigh a switch differently from someone whose current medication has not eased symptoms.

Timing is another part of the conversation. Pregnancy stage helps identify the exposure period being considered, while the medication and dose identify the treatment being assessed. Discuss breastfeeding if it is part of your plan. Sertraline is generally considered a first-line antidepressant partly because little of it passes into breast milk.

Your preferences matter alongside clinical details. You might prioritize staying on a medication that has worked, reducing a side effect, or considering a treatment with different pregnancy evidence. Say what worries you most, whether that is relapse, fetal exposure, or postpartum symptoms. A clear priority helps focus the options.

Bring these points into the appointment:

• Your diagnosis, current symptoms, and any recent changes.
• The exact medication and dose, plus previous treatments and responses.
• Past relapses or problems during a medication change.
• Your pregnancy stage and plans for breastfeeding or postpartum care.
• Your main concerns and preferences about continuing, switching, or tapering.

Use the discussion to compare the benefits and risks of each path, including the possibility that switching could increase relapse risk. Before stopping or changing an antidepressant, contact your prescriber to discuss a plan. A plan should also cover which symptoms to watch for and how treatment will be reviewed as your pregnancy and postpartum needs change.

Once your care plan is underway, you can also prepare for practical needs during pregnancy with this pregnancy product buyer’s guide.

Pregnancy Magazine

Pregnancy Magazine offers supportive reading to help you understand pregnancy and prepare for conversations about your care. Its articles cover prenatal health, wellness, and family topics, while sponsored editorial content and affiliate-supported coverage can introduce readers to relevant products and resources.

Use this guide to organize questions about medication history, symptom changes, and treatment preferences before speaking with your healthcare provider. Pregnancy Magazine provides general information, not personal medical consultations, so discuss medication decisions with your care team.

For questions about Pregnancy Magazine’s content or editorial partnerships, contact Pregnancy Magazine.

Carry a thoughtful plan into your next conversation

Whether antidepressants are safe during pregnancy depends on how potential medication effects compare with your mental health needs. You don’t need to resolve every part of that decision in one sitting. Write down what feels most uncertain, then bring that concern to a conversation with your healthcare provider.

Your needs or preferences may change as your pregnancy progresses. Notice meaningful shifts in your symptoms and revisit the treatment plan, including how it will support you after birth. Ongoing conversations can help keep your care connected to your day-to-day life, rather than leaving you with a decision made once and never reviewed.

For another practical part of preparing for pregnancy, explore the pregnancy product buyer’s guide. And remember, asking for help with your mental health is a caring step for you and your family. You deserve support as you find the path that feels right.

Frequently Asked Questions

Are some antidepressants safer or riskier than others?

Yes, the evidence differs by medication, exposure timing, and outcome. For example, some studies link first-trimester paroxetine exposure to a small risk of cardiovascular defects, while sertraline is often considered when breastfeeding because little passes into breast milk. These examples do not establish a universal ranking. Whether antidepressants are safe during pregnancy is best considered drug by drug and alongside your treatment history.

Are there other strategies for a pregnant person who doesn’t want to take medication but would like help with depression?

Yes. You can discuss options such as psychotherapy or counseling, along with practical support from trusted family members. These approaches may be considered alone or alongside medication, depending on your symptoms and history. For example, you might ask about therapy while also making a plan for what to do if symptoms worsen. If you’re already taking an antidepressant, talk with your prescriber before stopping or changing it while exploring other approaches.

Are there studies that analyze the impacts on children who were exposed to antidepressants in utero?

Yes. Studies have examined outcomes ranging from newborn adjustment to later development. When reading a finding, look at which medication and outcome researchers studied. A report about attention or learning, for example, does not answer every question about a child’s health. Studies also cannot predict one child’s future with certainty. Keep the study’s specific focus in mind when discussing how it relates to your pregnancy and treatment choices.

Can untreated depression affect newborns?

Untreated or undertreated depression during pregnancy is associated with preterm birth and low birth weight, which can affect a newborn’s start in life. This association describes a possible risk, not a prediction about any individual pregnancy. If symptoms make daily life difficult, share specific changes with your care team, such as trouble managing routines or feeling unable to cope, so those concerns can inform your care.

Is it okay to stop using antidepressants during pregnancy?

Before stopping or changing an antidepressant during pregnancy, talk with the prescriber. Abruptly stopping an SSRI can cause discontinuation symptoms such as nausea, insomnia, and flu-like feelings, and may increase relapse risk. If you’d like to stop, discuss a gradual taper with your healthcare provider. Before making changes, write down what is prompting the decision, any recent symptom changes, and questions about how a taper could affect your mental health.

Stay with the Same Treatment or Switch?

Continuing a treatment that has worked may be a reasonable option to discuss, while switching may make sense when symptoms remain difficult or side effects are a concern. Compare your past response and current symptoms with the safety evidence for each medication. For example, a switch may offer a different exposure profile, but it can also disrupt symptom control. Talk through both possibilities before changing treatment.

What are the risks of untreated depression and other mental health disorders during pregnancy?

Untreated or undertreated depression is associated with preterm birth and low birth weight, and untreated depression during pregnancy is identified as a major risk factor for postpartum depression. Anxiety can also need care, but specific risks depend on the condition and the person’s circumstances. Describe your symptoms, how they affect daily life, and any past mental health treatment so the conversation can focus on your needs.

Which antidepressants are considered safest during pregnancy?

There isn’t one antidepressant that is safest for everyone. Sertraline is often considered a first-line option, particularly when breastfeeding is part of the plan, while some studies associate first-trimester paroxetine exposure with a small risk of cardiovascular defects. These details are starting points for a personal discussion, not instructions to start or switch medicines. Your diagnosis, previous treatment response, symptoms, and preferences all matter.